Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors. 2010

Vijay M Khedkar, and Premlata K Ambre, and Jitender Verma, and Mushtaque S Shaikh, and Raghuvir R S Pissurlenkar, and Evans C Coutinho
Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Kalina, Santacruz (E), Mumbai, 400098, India.

HIV-1 protease is an obligatory enzyme in the replication process of the HIV virus. The abundance of structural information on HIV-1PR has made the enzyme an attractive target for computer-aided drug design strategies. The daunting ability of the virus to rapidly generate resistant mutants suggests that there is an ongoing need for new HIV-1PR inhibitors with better efficacy profiles and reduced toxicity. In the present investigation, molecular modeling studies were performed on a series of 54 cyclic urea analogs with symmetric P2/P2' substituents. The binding modes of these inhibitors were determined by docking. The docking results also provided a reliable conformational superimposition scheme for the 3D-QSAR studies. To gain insight into the steric, electrostatic, hydrophobic and hydrogen-bonding properties of these molecules and their influence on the inhibitory activity, comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were performed. Two different alignment schemes viz. receptor-based and atom-fit alignment, were used in this study to build the QSAR models. The derived 3D-QSAR models were found to be robust with statistically significant r(2) and r(2)(pred) values and have led to the identification of regions important for steric, hydrophobic and electronic interactions. The predictive ability of the models was assessed on a set of molecules that were not included in the training set. Superimposition of the 3D-contour maps generated from these models onto the active site of enzyme provided additional insight into the structural requirements of these inhibitors. The CoMFA and CoMSIA models were used to design some new inhibitors with improved binding affinity. Pharmacokinetic and toxicity predictions were also carried out for these molecules to gauge their ADME and safety profile. The computational results may open up new avenues for synthesis of potent HIV-1 protease inhibitors.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006860 Hydrogen Bonding A low-energy attractive force between hydrogen and another element. It plays a major role in determining the properties of water, proteins, and other compounds. Hydrogen Bonds,Bond, Hydrogen,Hydrogen Bond
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular

Related Publications

Vijay M Khedkar, and Premlata K Ambre, and Jitender Verma, and Mushtaque S Shaikh, and Raghuvir R S Pissurlenkar, and Evans C Coutinho
March 2009, Chemical biology & drug design,
Vijay M Khedkar, and Premlata K Ambre, and Jitender Verma, and Mushtaque S Shaikh, and Raghuvir R S Pissurlenkar, and Evans C Coutinho
December 2008, Bioorganic & medicinal chemistry letters,
Vijay M Khedkar, and Premlata K Ambre, and Jitender Verma, and Mushtaque S Shaikh, and Raghuvir R S Pissurlenkar, and Evans C Coutinho
June 2008, Archiv der Pharmazie,
Vijay M Khedkar, and Premlata K Ambre, and Jitender Verma, and Mushtaque S Shaikh, and Raghuvir R S Pissurlenkar, and Evans C Coutinho
May 2013, Chemistry Central journal,
Vijay M Khedkar, and Premlata K Ambre, and Jitender Verma, and Mushtaque S Shaikh, and Raghuvir R S Pissurlenkar, and Evans C Coutinho
November 2009, European journal of medicinal chemistry,
Vijay M Khedkar, and Premlata K Ambre, and Jitender Verma, and Mushtaque S Shaikh, and Raghuvir R S Pissurlenkar, and Evans C Coutinho
May 2024, Chemico-biological interactions,
Vijay M Khedkar, and Premlata K Ambre, and Jitender Verma, and Mushtaque S Shaikh, and Raghuvir R S Pissurlenkar, and Evans C Coutinho
January 2021, Current HIV research,
Vijay M Khedkar, and Premlata K Ambre, and Jitender Verma, and Mushtaque S Shaikh, and Raghuvir R S Pissurlenkar, and Evans C Coutinho
January 2007, Expert opinion on drug discovery,
Vijay M Khedkar, and Premlata K Ambre, and Jitender Verma, and Mushtaque S Shaikh, and Raghuvir R S Pissurlenkar, and Evans C Coutinho
November 2012, Molecular diversity,
Vijay M Khedkar, and Premlata K Ambre, and Jitender Verma, and Mushtaque S Shaikh, and Raghuvir R S Pissurlenkar, and Evans C Coutinho
August 2006, SAR and QSAR in environmental research,
Copied contents to your clipboard!